Recent News

• 03.11.2025 - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
• 03.11.2025 - Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results
• 03.05.2025 - TD Cowen 45th Annual Health Care Conference
• 03.05.2025 - TD Cowen 45th Annual Health Care Conference
• 03.05.2025 - Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
• 03.05.2025 - Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors
• 02.26.2025 - Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
• 02.26.2025 - Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences
• 02.12.2025 - Oppenheimer 35th Annual Healthcare Life Sciences Conference
• 02.12.2025 - Oppenheimer 35th Annual Healthcare Life Sciences Conference

Recent Filings

• 03.05.2025 - 8-K Current report
• 03.05.2025 - 3 Initial statement of beneficial ownership of securities
• 03.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.05.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.04.2025 - 4 Statement of changes in beneficial ownership of securities